Compare SUNS & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | CRDF |
|---|---|---|
| Founded | 2023 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.5M | 114.5M |
| IPO Year | N/A | 2012 |
| Metric | SUNS | CRDF |
|---|---|---|
| Price | $9.36 | $1.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $12.00 | $9.63 |
| AVG Volume (30 Days) | 61.4K | ★ 989.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.70% | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | $165.88 | N/A |
| Revenue Next Year | $46.38 | N/A |
| P/E Ratio | $8.84 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $7.80 | $1.48 |
| 52 Week High | $12.19 | $4.56 |
| Indicator | SUNS | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 51.82 |
| Support Level | $9.31 | $1.48 |
| Resistance Level | $9.65 | $2.41 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 53.52 | 78.64 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.